Compare NICE & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NICE | DFTX |
|---|---|---|
| Founded | 1986 | N/A |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 5.9B |
| IPO Year | 1999 | 2020 |
| Metric | NICE | DFTX |
|---|---|---|
| Price | $91.60 | $29.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 19 |
| Target Price | ★ $127.54 | $72.83 |
| AVG Volume (30 Days) | 569.0K | ★ 1.5M |
| Earning Date | 11-04-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.91 | N/A |
| Revenue Next Year | $7.78 | N/A |
| P/E Ratio | $11.21 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $83.10 | $14.62 |
| 52 Week High | $135.55 | $49.70 |
| Indicator | NICE | DFTX |
|---|---|---|
| Relative Strength Index (RSI) | 27.87 | 34.77 |
| Support Level | $86.27 | $20.43 |
| Resistance Level | $104.84 | $37.72 |
| Average True Range (ATR) | 3.97 | 2.14 |
| MACD | -1.55 | -0.39 |
| Stochastic Oscillator | 10.68 | 6.45 |
Nice is an enterprise software company that serves the customer engagement and financial crime and compliance markets. Software is deployed primarily on the cloud, but also on premises. Within customer engagement, Nice's CXone is the leading CCaaS platform providing solutions such as call routing, interactive voice response, digital self-service, and workforce engagement management. Within financial crime and compliance, Nice offers risk and investigation management, fraud prevention, anti-money-laundering, and compliance solutions.
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.